The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016 Consortium of Multiple
Sclerosis Centres guidelines on the use of MRI in diagnosis and monitoring of multiple …

… In contrast, demyelinated inactive lesions (C) have only a few scattered phagocytes within
the lesions (G). Note the presence of concentrated phagocytes in the myelinated normal-…

In patients with multiple sclerosis (MS), grey matter damage is widespread and might underlie
many of the clinical symptoms, especially cognitive impairment. This relation between …

Objective: To assess the time course of brain atrophy and the difference across clinical
subtypes in multiple sclerosis (MS). Methods: The percent brain volume change (PBVC) was …

Objectives: To determine the rate of brain atrophy in neurologically asymptomatic elderly and
to investigate the impact of baseline variables including conventional cerebrovascular risk …

Objective Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We
investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with …

… C. Enzinger has received funding for travel, speaker honoraria, or research funding from
Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Genzyme, and Teva …

Background and objective: We explored which clinical and biochemical variables predict
conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (CDMS…

Objective To determine whether brain atrophy and lesion volumes predict subsequent 10
year clinical evolution in multiple sclerosis (MS). Design From eight MAGNIMS (MAGNetic …

Background and Purpose— Strokes have especially devastating implications if they occur
early in life; however, only limited information exists on the characteristics of acute …